MedTrace Logo

Prophylactic Anticoagulation for Catheter-related Thrombosis

NCT04256525 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1640

Last updated 2020-06-30

No results posted yet for this study

Summary

The main objective of this study is to compare the efficacy and safety of aspirin, low molecule heparin and rivaroxaban for preventing catheter-related thrombosis in middle-to-high-risk ambulatory patients with cancer and implantable venous access ports.

Conditions

  • Venous Thrombosis Due to Central Venous Access Device (Disorder)
  • Prophylactic Anticoagulation
  • Patients With Tumor

Interventions

DRUG

Rivaroxaban 10mg

10mg orally per day

DRUG

Aspirin 100mg

100mg orally per day

DRUG

low molecule heparin

0.4ml per day subcutaneous injection

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Jian Huang, Doctor · Second Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-08-30
Completion
2022-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04256525 on ClinicalTrials.gov